FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2032967017> ?p ?o ?g. }

• W2032967017 endingPage "527" @default.
• W2032967017 startingPage "515" @default.
• W2032967017 abstract "A murine monoclonal anti-idiotype (Id) antibody, 3H1 has been developed and characterized previously. Anti-Id 3H1 mimics a specific epitope of carcinoembryonic antigen (CEA) and can be used as a surrogate antigen for CEA. 3H1 induced anti-CEA immunity in different species of animals as well as humans and showed promise as a potential vaccine candidate in phase I/II clinical trials for colon cancer patients. One area of interest to us has been the development of new immune adjuvants that may augment the potency of 3H1 as a tumor vaccine. Oligodeoxynucleotides containing unmethylated CpG motifs (CpG ODN) are potent immunostimulatory agents capable of enhancing the Ag-specific Th1 response when used as immune adjuvants. In this study, we have evaluated the efficacy of 3H1 as a tumor vaccine when admixed with a select CpG ODN 1826 in transgenic mice that express human CEA. The vaccine potential of 3H1 was also assessed in the presence of another widely used adjuvant, QS-21. 3H1 coupled to keyhole limpet hemocyanin (KLH) and mixed with Freund's adjuvant (FA) was used as a gold standard in this system. 3H1 vaccination with different adjuvants induced both humoral and cellular anti-3H1, as well as anti-CEA immunity in CEA transgenic mice. The immune sera could lyse CEA-transfected murine colon carcinoma cells, C15 effectively in an antibody-dependent cellular cytotoxicity assay. The anti-CEA antibody responses were somewhat comparable in each adjuvant-treated group of mice, whereas cellular immune responses were significantly greater when CpG was used as an adjuvant. Splenocytes obtained from 3H1-CpG-immunized mice showed an increased proliferative CD4(+) Th1-type T-cell response when stimulated in vitro with 3H1 or CEA and secreted elevated levels of Th1 cytokines (IL-2, IFN-gamma). This vaccine also induced MHC class I antigen-restricted CD8(+) T-cell responses. In a solid tumor model, C15 tumor growth was significantly inhibited by 3H1 vaccinations. In 3H1-CpG-vaccinated mice, the duration of survival was, however, longer compared to the 3H1-QS21-vaccinated mice. These findings suggest that 3H1-CpG vaccinations can break peripheral tolerance to CEA and induce protective antitumor immunity in this murine model transgenic for human CEA." @default.
• W2032967017 created "2016-06-24" @default.
• W2032967017 creator A5000767624 @default.
• W2032967017 creator A5001607309 @default.
• W2032967017 creator A5005880847 @default.
• W2032967017 creator A5026521311 @default.
• W2032967017 creator A5035080821 @default.
• W2032967017 creator A5039812436 @default.
• W2032967017 creator A5040723719 @default.
• W2032967017 creator A5044423598 @default.
• W2032967017 creator A5063597228 @default.
• W2032967017 creator A5073403338 @default.
• W2032967017 date "2005-07-26" @default.
• W2032967017 modified "2023-10-10" @default.
• W2032967017 title "CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice" @default.
• W2032967017 cites W1514540900 @default.
• W2032967017 cites W1536249747 @default.
• W2032967017 cites W1644577573 @default.
• W2032967017 cites W1850867399 @default.
• W2032967017 cites W1935511302 @default.
• W2032967017 cites W1969061981 @default.
• W2032967017 cites W1983806918 @default.
• W2032967017 cites W1994634265 @default.
• W2032967017 cites W1995801872 @default.
• W2032967017 cites W2010222913 @default.
• W2032967017 cites W2022388918 @default.
• W2032967017 cites W2030689421 @default.
• W2032967017 cites W2036310178 @default.
• W2032967017 cites W2054037411 @default.
• W2032967017 cites W2084613693 @default.
• W2032967017 cites W2092128665 @default.
• W2032967017 cites W2092237412 @default.
• W2032967017 cites W2099296219 @default.
• W2032967017 cites W2100593890 @default.
• W2032967017 cites W2101240557 @default.
• W2032967017 cites W2105270641 @default.
• W2032967017 cites W2106414148 @default.
• W2032967017 cites W2109715458 @default.
• W2032967017 cites W2118011548 @default.
• W2032967017 cites W317612959 @default.
• W2032967017 doi "https://doi.org/10.1007/s00262-005-0009-6" @default.
• W2032967017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16044253" @default.
• W2032967017 hasPublicationYear "2005" @default.
• W2032967017 type Work @default.
• W2032967017 sameAs 2032967017 @default.
• W2032967017 citedByCount "23" @default.
• W2032967017 countsByYear W20329670172012 @default.
• W2032967017 countsByYear W20329670172014 @default.
• W2032967017 countsByYear W20329670172016 @default.
• W2032967017 countsByYear W20329670172020 @default.
• W2032967017 crossrefType "journal-article" @default.
• W2032967017 hasAuthorship W2032967017A5000767624 @default.
• W2032967017 hasAuthorship W2032967017A5001607309 @default.
• W2032967017 hasAuthorship W2032967017A5005880847 @default.
• W2032967017 hasAuthorship W2032967017A5026521311 @default.
• W2032967017 hasAuthorship W2032967017A5035080821 @default.
• W2032967017 hasAuthorship W2032967017A5039812436 @default.
• W2032967017 hasAuthorship W2032967017A5040723719 @default.
• W2032967017 hasAuthorship W2032967017A5044423598 @default.
• W2032967017 hasAuthorship W2032967017A5063597228 @default.
• W2032967017 hasAuthorship W2032967017A5073403338 @default.
• W2032967017 hasBestOaLocation W20329670171 @default.
• W2032967017 hasConcept C104317684 @default.
• W2032967017 hasConcept C121608353 @default.
• W2032967017 hasConcept C147483822 @default.
• W2032967017 hasConcept C150194340 @default.
• W2032967017 hasConcept C159654299 @default.
• W2032967017 hasConcept C190727270 @default.
• W2032967017 hasConcept C195616568 @default.
• W2032967017 hasConcept C203014093 @default.
• W2032967017 hasConcept C22801619 @default.
• W2032967017 hasConcept C2776662205 @default.
• W2032967017 hasConcept C2777387746 @default.
• W2032967017 hasConcept C2777701055 @default.
• W2032967017 hasConcept C2777863537 @default.
• W2032967017 hasConcept C54355233 @default.
• W2032967017 hasConcept C55493867 @default.
• W2032967017 hasConcept C86803240 @default.
• W2032967017 hasConcept C8891405 @default.
• W2032967017 hasConceptScore W2032967017C104317684 @default.
• W2032967017 hasConceptScore W2032967017C121608353 @default.
• W2032967017 hasConceptScore W2032967017C147483822 @default.
• W2032967017 hasConceptScore W2032967017C150194340 @default.
• W2032967017 hasConceptScore W2032967017C159654299 @default.
• W2032967017 hasConceptScore W2032967017C190727270 @default.
• W2032967017 hasConceptScore W2032967017C195616568 @default.
• W2032967017 hasConceptScore W2032967017C203014093 @default.
• W2032967017 hasConceptScore W2032967017C22801619 @default.
• W2032967017 hasConceptScore W2032967017C2776662205 @default.
• W2032967017 hasConceptScore W2032967017C2777387746 @default.
• W2032967017 hasConceptScore W2032967017C2777701055 @default.
• W2032967017 hasConceptScore W2032967017C2777863537 @default.
• W2032967017 hasConceptScore W2032967017C54355233 @default.
• W2032967017 hasConceptScore W2032967017C55493867 @default.
• W2032967017 hasConceptScore W2032967017C86803240 @default.
• W2032967017 hasConceptScore W2032967017C8891405 @default.
• W2032967017 hasIssue "5" @default.
• W2032967017 hasLocation W20329670171 @default.

• next